What Is Janoshik Testing and How Do I Verify a Report?

Janoshik Analytical is an independent third-party laboratory that many research peptide suppliers use to test purity and identity of their material. You verify a report by checking three separate things: that the document itself is authentic (the report identifier resolves through the lab's own verification, or the lab confirms it directly), that it corresponds to the exact batch or lot number printed on the vial you are actually buying, and that the panels run cover the contaminants you care about, not just purity. A real report attached to the wrong lot tells you nothing useful, and that is the most common failure a wholesale buyer runs into.

That distinction matters because third-party testing has become purchasing shorthand in this category. A lab name on a product page reads as proof, and buyers rarely have the tooling to confirm it. If you are placing volume orders and reselling research compounds into your own catalog, the report is the only technical evidence you have about what is in the vial. It deserves the same scrutiny you would apply to any other supplier document.

Why a laboratory name became a trust proxy

Research peptides are sold as research-use-only materials. They are not FDA-approved drugs, and no regulator is checking every lot of every compound on the market. That gap created demand for outside verification, and independent analytical labs filled it. A supplier submits a sample, the lab runs its instruments, and the resulting certificate of analysis becomes the document a buyer relies on.

The weakness is structural. The supplier chooses what to submit, chooses which panels to pay for, and chooses which reports to publish. None of that is fraud on its own; it is simply how commercial testing works. But it means the lab name alone carries no information. What carries information is a specific report, tied to a specific lot, with a scope you can read, that you were able to confirm independently.

What the laboratory actually measures

Analytical testing for peptide material generally covers two separate questions, and buyers frequently conflate them.

The first is identity: is this molecule what the label says it is? That is usually answered by mass spectrometry, which confirms the molecular weight matches the expected structure. The second is purity: what percentage of the material is the target compound versus everything else? That is typically answered by high-performance liquid chromatography, or HPLC, which separates the sample into its components and quantifies them.

Beyond those two, additional panels can be ordered (testing for endotoxin, sterility, heavy metals, residual solvents, or water content, among others). These are usually priced separately and are not automatically included. A report showing excellent purity says nothing about heavy metals if heavy metals were never tested. Read the scope before you read the result.

One more nuance worth understanding: research suggests that HPLC purity figures are method-dependent, meaning the column, gradient, and detection wavelength all influence the number. Two labs testing the same material can report slightly different figures without either being wrong. This is why the method disclosure on a report matters as much as the headline percentage.

Reading a report field by field

If a document you have been sent is missing three or more of these fields, it is not a certificate of analysis in any meaningful sense. It is a marketing graphic.

Four checks that turn a PDF into evidence

Confirm the document is authentic. Reports from established analytical labs carry a unique reference number, and many include a scannable code. The check is simple: does that identifier resolve through the laboratory's own systems, and does any embedded link point to the lab's actual domain rather than a lookalike? If you cannot confirm it that way, contact the laboratory directly with the report number and ask them to confirm it exists. Labs field these requests from buyers routinely. A PDF is trivially editable; the identifier is the part that is hard to fake.

Match the lot, not the compound. This is where most verification collapses. A supplier sends you a genuine report for BPC-157, and the vial that arrives carries a different lot number. The report is real. It just describes material you did not buy. Ask for the report that corresponds to the lot you will be shipped, and if you are ordering against future stock, ask what happens when the lot changes mid-contract.

Check the date against the stock. Peptide material has a shelf life and storage requirements. A report dated years before your purchase, applied to inventory that has been sitting since, is thin evidence. You want testing that is contemporaneous with the production run you are receiving.

Read the scope, then ask what is missing. A single-panel purity report is a partial picture. If your buyers or your own quality process care about contaminants, you need panels that address them. Ask the supplier which panels they run as standard on every batch versus which they run occasionally, and ask whether the tested sample was drawn from the production batch or submitted separately.

Chain of custody sits underneath all four checks. The strongest arrangement is one where samples are pulled from finished production lots and submitted routinely, not where a supplier sends a single flattering sample once and reuses the resulting document indefinitely.

Practices worth walking away from

You can contrast supplier behavior without naming anyone, and a few patterns should end a conversation.

Cropped screenshots instead of full documents. If you are shown a purity figure with the header, lot number, and date cut off, you have been shown nothing. Testing available on request, where the request is never quite fulfilled, or where you are told reports are proprietary. Charging separately for a certificate of analysis, which reframes basic quality documentation as an upsell. In-house tested with no method, no instrument, and no way to distinguish it from an assertion.

Hidden wholesale pricing belongs on the same list. It is not a testing issue, but it comes from the same place: a supplier who will not put numbers in front of you before you commit is a supplier who expects the terms to be negotiated from an information disadvantage. If tier structure, minimums, and lead times are not stated plainly, ask why.

What to ask before you commit to volume

Bring a short list to every supplier conversation. Do you test every production batch, or do you test periodically? Which panels are standard? Can I see the report for the specific lot I would receive, before the order ships? Are your reports published where I can check them without asking? What is your process when a batch fails? Who handles the shipment, and how long from order to arrival?

Separately, and this is the part no supplier can answer for you, resale of research compounds sits inside a regulatory picture that varies. Whether your particular business model, licensing status, and customer base allow you to stock and resell these materials is a question for your own attorney and, where relevant, your state board or professional licensing body. What labeling, recordkeeping, and disclosure obligations attach to your operation? Does your business license contemplate this category of product at all? Those are questions to resolve with counsel before you place an order, not afterward. This article is informational and is not legal advice, and no supplier's compliance posture substitutes for your own.

What Real Peptides does differently

Real Peptides publishes its lab results publicly rather than holding them behind a request form. Buyers can check the certificates of analysis themselves, which is the entire point of third-party verification: a document you have to ask permission to see is not verification, it is a courtesy.

Every batch runs through 7-panel testing, and material is held to a 99%+ HPLC purity standard. Because the reports are posted rather than emailed on request, the batch-matching check described above is something a prospective partner can perform before the first conversation, not after the first invoice. That applies across the catalog; the same documentation standard sits behind widely stocked compounds like BPC-157 and GHK-Cu as behind less common items in the growth factor and tissue signaling research range.

Fulfillment runs from the US in 5-7 days, which matters for buyers who have been burned by indefinite international transit and unclear customs exposure. Wholesale onboarding is a 3-step application rather than an open-ended sales cycle. All compounds are supplied for laboratory and research use only; they are not FDA-approved drugs and are not sold for human consumption.

None of that removes your obligation to verify. It just means verification is possible without a negotiation.

Where this leaves your sourcing decision

If you are stocking research compounds for resale, the practical test of a supplier is whether their documentation survives your scrutiny before money changes hands. Ask for the lot-specific report, confirm it with the laboratory, read the scope, and check the date. A supplier who makes that easy is telling you something about how they operate. A supplier who makes it difficult is telling you the same thing.

Buyers who have run those checks and want to see tier pricing, minimums, and current lot documentation can move to the application step; the Wholesale Partner Program is built for businesses evaluating supply at volume, and the review process is designed to be short.

For program terms and tier structure, see the wholesale peptides program page, or apply for a wholesale account to begin the 3-step review.